Machine Nation News Team
May 19, 2025 at 10:15:00 AM
The New Jersey Company Will Build A 470,000-Square-Foot Commercial Production Facility, Which Will Make Biologics And Become The “Future U.S. Home” For Its Megablockbuster Cancer Treatment Keytruda, Merck Said In Its Announcement
Merck & Co., headquartered in Rahway, New Jersey, broke ground on April 29, 2025, for a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware, named Merck Wilmington Biotech. The facility, set to be the “future U.S. home” for Keytruda, Merck’s megablockbuster cancer immunotherapy generating $25 billion annually, will focus on commercial production of biologics and launch capabilities for new therapies. Slated for completion by 2027, the plant will include laboratory, manufacturing, and warehouse spaces, creating 500 direct jobs and over 1,000 construction jobs, boosting Delaware’s 20,000-strong manufacturing workforce. Supported by state incentives and the 2022 CHIPS and Science Act, the project addresses a $50 billion biologics market, driven by demand for cancer treatments. CEO Robert Davis emphasized “strengthening domestic manufacturing” amid President Trump’s 10% tariffs, reducing reliance on global supply chains. The facility aligns with Merck’s $30 billion R&D investment through 2025, enhancing production resilience for Keytruda and other biologics.
For the precision machining industry, Merck’s facility highlights the critical role of cutting speed in biologics manufacturing. Producing equipment components, such as bioreactor fittings and filtration housings, requires CNC milling with optimized cutting speeds, typically 100–500 surface feet per minute (SFM) for stainless steel, to achieve precise tolerances within ±0.001 inches and smooth surface finishes. 5-axis milling machines, programmed with specific cutting speeds and feed rates, ensure efficient material removal for high-volume production with real-time quality control. The facility’s scale drives demand for local machine shops to supply precision tooling, adopting Industry 4.0 technologies like AI-driven milling and additive manufacturing. As part of a $50 billion precision manufacturing market, this project creates opportunities for suppliers in Delaware, where manufacturing jobs have grown 2% since 2022, strengthening supply chains for pharmaceutical production.
Source:
Social Media Buzz (powered by X):
X is abuzz with Merck’s Delaware facility, with posts on May 18, 2025, calling it a “landmark” for U.S. pharma. Users praised the 500 jobs, with one noting “Keytruda’s new home boosts Delaware,” while another tied it to “reshoring biologics.” The excitement reflects optimism for economic growth and healthcare innovation.
What is the Cutting Speed?
This is one of many key terms of our broad Machine Nation Essential Modern Precision Industries Guidebook (MPIG). Click here to get a copy straight to your inbox.
Cutting Speed - The velocity at which a CNC milling tool cuts material, measured in surface feet per minute (SFM), critical for achieving precision and efficiency in component production.
Why do we think that sustainability should be a core focus of your business?
At Machine Nation, we empower machine shops with cutting-edge insights, solutions, and technology to drive efficiency, precision, and profitability. From industry news to expert-driven strategies, we help manufacturers stay ahead in an evolving landscape. Partner with us to optimize your operations and shape the future of precision machining.
Related Tags:
#MerckKeytruda #DelawareManufacturing #CuttingSpeed #PrecisionMachining #Biologics #Reshoring